Transfemoral aortic valve implantation: New criteria to predict vascular complications

Kentaro Hayashida, Thierry Lefvre, Bernard Chevalier, Thomas Hovasse, Mauro Romano, Philippe Garot, Darren Mylotte, Jhonathan Uribe, Arnaud Farge, Patrick Donzeau-Gouge, Erik Bouvier, Bertrand Cormier, Marie Claude Morice

Research output: Contribution to journalArticle

311 Citations (Scopus)

Abstract

Objectives: This study sought to evaluate the incidence, impact, and predictors of vascular complications in transcatheter aortic valve implantation (TAVI). Background: Vascular complications increase morbidity and mortality in transfemoral TAVI; however, there remains a paucity of data describing these serious events. Methods: We performed a prospective cohort study of 130 consecutive transfemoral TAVI recipients. Vascular complications were defined by the Valve Academic Research Consortium (VARC) criteria. The ratio of the sheath outer diameter (in millimeters) to the minimal femoral artery diameter (in millimeters) defined the sheath to femoral artery ratio (SFAR). Results: In our cohort of elderly patients (83.3 ± 5.9 years), the logistic EuroScore was 25.8% ± 11.9%. The Edwards valve was used in 102 cases (18- to 24-F) and the CoreValve in 27 (18-F). The minimal femoral artery diameter was 8.17 ± 1.14 mm, and the calcification (0 to 3) and tortuosity scores (0 to 3) were 0.58 ± 0.72 and 0.28 ± 0.53, respectively. The mean sheath diameter was 8.10 ± 0.82 mm, and the mean SFAR was 0.99 ± 0.16. Vascular complications occurred in 27.6% (VARC major: 17.3%, minor: 10.2%), and major vascular complications predicted 30-day mortality (22.7% vs. 7.6%, p = 0.049). The SFAR (hazard ratio [HR]: 186.20, 95% confidence interval [CI]: 4.41 to 7,855.11), center experience (HR: 3.66, 95% CI: 1.17 to 11.49), and femoral calcification (HR: 3.44, 95% CI: 1.16 to 10.17) predicted major complications by multivariate analysis. An SFAR threshold of 1.05 (area under the curve = 0.727) predicted a higher rate of VARC major complications (30.9% vs. 6.9%, p = 0.001) and 30-day mortality (18.2% vs. 4.2%, p = 0.016). Conclusions: Vascular complications in transfemoral TAVI are relatively frequent. VARC major vascular complications increase 30-day mortality and are predicted by experience, femoral calcification, and SFAR. Routine application of SFAR will improve patient selection for transfemoral TAVI and may improve outcome.

Original languageEnglish
Pages (from-to)851-858
Number of pages8
JournalJACC: Cardiovascular Interventions
Volume4
Issue number8
DOIs
Publication statusPublished - 2011 Aug
Externally publishedYes

Fingerprint

Femoral Artery
Aortic Valve
Blood Vessels
Mortality
Confidence Intervals
Thigh
Research
Patient Selection
Area Under Curve
Cohort Studies
Multivariate Analysis
Transcatheter Aortic Valve Replacement
Prospective Studies
Morbidity
Incidence

Keywords

  • aortic stenosis
  • balloon valvuloplasty
  • risk factors
  • transcatheter aortic valve implantation
  • vascular complications

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Hayashida, K., Lefvre, T., Chevalier, B., Hovasse, T., Romano, M., Garot, P., ... Morice, M. C. (2011). Transfemoral aortic valve implantation: New criteria to predict vascular complications. JACC: Cardiovascular Interventions, 4(8), 851-858. https://doi.org/10.1016/j.jcin.2011.03.019

Transfemoral aortic valve implantation : New criteria to predict vascular complications. / Hayashida, Kentaro; Lefvre, Thierry; Chevalier, Bernard; Hovasse, Thomas; Romano, Mauro; Garot, Philippe; Mylotte, Darren; Uribe, Jhonathan; Farge, Arnaud; Donzeau-Gouge, Patrick; Bouvier, Erik; Cormier, Bertrand; Morice, Marie Claude.

In: JACC: Cardiovascular Interventions, Vol. 4, No. 8, 08.2011, p. 851-858.

Research output: Contribution to journalArticle

Hayashida, K, Lefvre, T, Chevalier, B, Hovasse, T, Romano, M, Garot, P, Mylotte, D, Uribe, J, Farge, A, Donzeau-Gouge, P, Bouvier, E, Cormier, B & Morice, MC 2011, 'Transfemoral aortic valve implantation: New criteria to predict vascular complications', JACC: Cardiovascular Interventions, vol. 4, no. 8, pp. 851-858. https://doi.org/10.1016/j.jcin.2011.03.019
Hayashida, Kentaro ; Lefvre, Thierry ; Chevalier, Bernard ; Hovasse, Thomas ; Romano, Mauro ; Garot, Philippe ; Mylotte, Darren ; Uribe, Jhonathan ; Farge, Arnaud ; Donzeau-Gouge, Patrick ; Bouvier, Erik ; Cormier, Bertrand ; Morice, Marie Claude. / Transfemoral aortic valve implantation : New criteria to predict vascular complications. In: JACC: Cardiovascular Interventions. 2011 ; Vol. 4, No. 8. pp. 851-858.
@article{8e61e006c2b94844871f2e40e2155e3d,
title = "Transfemoral aortic valve implantation: New criteria to predict vascular complications",
abstract = "Objectives: This study sought to evaluate the incidence, impact, and predictors of vascular complications in transcatheter aortic valve implantation (TAVI). Background: Vascular complications increase morbidity and mortality in transfemoral TAVI; however, there remains a paucity of data describing these serious events. Methods: We performed a prospective cohort study of 130 consecutive transfemoral TAVI recipients. Vascular complications were defined by the Valve Academic Research Consortium (VARC) criteria. The ratio of the sheath outer diameter (in millimeters) to the minimal femoral artery diameter (in millimeters) defined the sheath to femoral artery ratio (SFAR). Results: In our cohort of elderly patients (83.3 ± 5.9 years), the logistic EuroScore was 25.8{\%} ± 11.9{\%}. The Edwards valve was used in 102 cases (18- to 24-F) and the CoreValve in 27 (18-F). The minimal femoral artery diameter was 8.17 ± 1.14 mm, and the calcification (0 to 3) and tortuosity scores (0 to 3) were 0.58 ± 0.72 and 0.28 ± 0.53, respectively. The mean sheath diameter was 8.10 ± 0.82 mm, and the mean SFAR was 0.99 ± 0.16. Vascular complications occurred in 27.6{\%} (VARC major: 17.3{\%}, minor: 10.2{\%}), and major vascular complications predicted 30-day mortality (22.7{\%} vs. 7.6{\%}, p = 0.049). The SFAR (hazard ratio [HR]: 186.20, 95{\%} confidence interval [CI]: 4.41 to 7,855.11), center experience (HR: 3.66, 95{\%} CI: 1.17 to 11.49), and femoral calcification (HR: 3.44, 95{\%} CI: 1.16 to 10.17) predicted major complications by multivariate analysis. An SFAR threshold of 1.05 (area under the curve = 0.727) predicted a higher rate of VARC major complications (30.9{\%} vs. 6.9{\%}, p = 0.001) and 30-day mortality (18.2{\%} vs. 4.2{\%}, p = 0.016). Conclusions: Vascular complications in transfemoral TAVI are relatively frequent. VARC major vascular complications increase 30-day mortality and are predicted by experience, femoral calcification, and SFAR. Routine application of SFAR will improve patient selection for transfemoral TAVI and may improve outcome.",
keywords = "aortic stenosis, balloon valvuloplasty, risk factors, transcatheter aortic valve implantation, vascular complications",
author = "Kentaro Hayashida and Thierry Lefvre and Bernard Chevalier and Thomas Hovasse and Mauro Romano and Philippe Garot and Darren Mylotte and Jhonathan Uribe and Arnaud Farge and Patrick Donzeau-Gouge and Erik Bouvier and Bertrand Cormier and Morice, {Marie Claude}",
year = "2011",
month = "8",
doi = "10.1016/j.jcin.2011.03.019",
language = "English",
volume = "4",
pages = "851--858",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Transfemoral aortic valve implantation

T2 - New criteria to predict vascular complications

AU - Hayashida, Kentaro

AU - Lefvre, Thierry

AU - Chevalier, Bernard

AU - Hovasse, Thomas

AU - Romano, Mauro

AU - Garot, Philippe

AU - Mylotte, Darren

AU - Uribe, Jhonathan

AU - Farge, Arnaud

AU - Donzeau-Gouge, Patrick

AU - Bouvier, Erik

AU - Cormier, Bertrand

AU - Morice, Marie Claude

PY - 2011/8

Y1 - 2011/8

N2 - Objectives: This study sought to evaluate the incidence, impact, and predictors of vascular complications in transcatheter aortic valve implantation (TAVI). Background: Vascular complications increase morbidity and mortality in transfemoral TAVI; however, there remains a paucity of data describing these serious events. Methods: We performed a prospective cohort study of 130 consecutive transfemoral TAVI recipients. Vascular complications were defined by the Valve Academic Research Consortium (VARC) criteria. The ratio of the sheath outer diameter (in millimeters) to the minimal femoral artery diameter (in millimeters) defined the sheath to femoral artery ratio (SFAR). Results: In our cohort of elderly patients (83.3 ± 5.9 years), the logistic EuroScore was 25.8% ± 11.9%. The Edwards valve was used in 102 cases (18- to 24-F) and the CoreValve in 27 (18-F). The minimal femoral artery diameter was 8.17 ± 1.14 mm, and the calcification (0 to 3) and tortuosity scores (0 to 3) were 0.58 ± 0.72 and 0.28 ± 0.53, respectively. The mean sheath diameter was 8.10 ± 0.82 mm, and the mean SFAR was 0.99 ± 0.16. Vascular complications occurred in 27.6% (VARC major: 17.3%, minor: 10.2%), and major vascular complications predicted 30-day mortality (22.7% vs. 7.6%, p = 0.049). The SFAR (hazard ratio [HR]: 186.20, 95% confidence interval [CI]: 4.41 to 7,855.11), center experience (HR: 3.66, 95% CI: 1.17 to 11.49), and femoral calcification (HR: 3.44, 95% CI: 1.16 to 10.17) predicted major complications by multivariate analysis. An SFAR threshold of 1.05 (area under the curve = 0.727) predicted a higher rate of VARC major complications (30.9% vs. 6.9%, p = 0.001) and 30-day mortality (18.2% vs. 4.2%, p = 0.016). Conclusions: Vascular complications in transfemoral TAVI are relatively frequent. VARC major vascular complications increase 30-day mortality and are predicted by experience, femoral calcification, and SFAR. Routine application of SFAR will improve patient selection for transfemoral TAVI and may improve outcome.

AB - Objectives: This study sought to evaluate the incidence, impact, and predictors of vascular complications in transcatheter aortic valve implantation (TAVI). Background: Vascular complications increase morbidity and mortality in transfemoral TAVI; however, there remains a paucity of data describing these serious events. Methods: We performed a prospective cohort study of 130 consecutive transfemoral TAVI recipients. Vascular complications were defined by the Valve Academic Research Consortium (VARC) criteria. The ratio of the sheath outer diameter (in millimeters) to the minimal femoral artery diameter (in millimeters) defined the sheath to femoral artery ratio (SFAR). Results: In our cohort of elderly patients (83.3 ± 5.9 years), the logistic EuroScore was 25.8% ± 11.9%. The Edwards valve was used in 102 cases (18- to 24-F) and the CoreValve in 27 (18-F). The minimal femoral artery diameter was 8.17 ± 1.14 mm, and the calcification (0 to 3) and tortuosity scores (0 to 3) were 0.58 ± 0.72 and 0.28 ± 0.53, respectively. The mean sheath diameter was 8.10 ± 0.82 mm, and the mean SFAR was 0.99 ± 0.16. Vascular complications occurred in 27.6% (VARC major: 17.3%, minor: 10.2%), and major vascular complications predicted 30-day mortality (22.7% vs. 7.6%, p = 0.049). The SFAR (hazard ratio [HR]: 186.20, 95% confidence interval [CI]: 4.41 to 7,855.11), center experience (HR: 3.66, 95% CI: 1.17 to 11.49), and femoral calcification (HR: 3.44, 95% CI: 1.16 to 10.17) predicted major complications by multivariate analysis. An SFAR threshold of 1.05 (area under the curve = 0.727) predicted a higher rate of VARC major complications (30.9% vs. 6.9%, p = 0.001) and 30-day mortality (18.2% vs. 4.2%, p = 0.016). Conclusions: Vascular complications in transfemoral TAVI are relatively frequent. VARC major vascular complications increase 30-day mortality and are predicted by experience, femoral calcification, and SFAR. Routine application of SFAR will improve patient selection for transfemoral TAVI and may improve outcome.

KW - aortic stenosis

KW - balloon valvuloplasty

KW - risk factors

KW - transcatheter aortic valve implantation

KW - vascular complications

UR - http://www.scopus.com/inward/record.url?scp=84860389030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860389030&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2011.03.019

DO - 10.1016/j.jcin.2011.03.019

M3 - Article

C2 - 21851897

AN - SCOPUS:84860389030

VL - 4

SP - 851

EP - 858

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 8

ER -